Par Pharmaceutical Receives Approval for Ondansetron Orally Disintegrating Tablets (PR Newswire via Yahoo! Finance)
Par Pharmaceutical Companies, Inc. today announced that it has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for ondansetron orally disintegrating tablets in 4 mg and 8 mg strengths.

Ranbaxy Granted Final FDA Approval To Market Simvastatin 5, 10, 20 And 40 Mg Tablets (Medical News Today)
Ranbaxy Laboratories Limited (RLL), announced today that the Company has received approval from the U.S. Food and Drug Administration (FDA) to manufacture and market Simvastatin Tablets USP, 5 mg, 10 mg, 20 mg and 40 mg in the U.S. [click link for full article]

Barr Confirms Generic Thalomid(R) Capsule, 50 mg and 100 mg Application (Boursorama)
WOODCLIFF LAKE, N.J., Dec. 26 /PRNewswire-FirstCall/ -- Barr Laboratories, Inc., a subsidiary of Barr Pharmaceuticals, Inc. , today confirmed that it is seeking approval from the U.S. Food & Drug Administration (FDA) to manufacture and market a generic version of Celgene Corporation's Thalomid(R) (thalidomide) Capsules, 50 mg and 100 mg.